Navigation Links
Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - Antisense Pharma today announced, that the abstract entitled “Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009” has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th.

In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week. “The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule”, explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session “Gastrointestinal (Noncolorectal) Cancer”. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization.


'"/>




Page: 1 2

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase data Systemic Application the TGF beta2 inhibitor Presented
(Date:8/28/2015)... N.J. , Aug. 28, 2015  IP Shakti, LLC, ... LLC. ... "Our new corporate identity signifies our transformation ... world,s first predictive analytics platform for patent claim validity." ... the launch of the proprietary AIA Shield™ platform, the Company ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015  Mylan ... its shareholders have approved Mylan,s proposed acquisition of ... and the related issuance of Mylan ordinary shares ... of shareholders held today. The transaction received the ... general meeting. In addition, the transaction received support ...
(Date:8/28/2015)... , August 28, 2015 Insights- ... seamlessly connects people, technologies and care protoc ols across ... and the cost of healthcare delivery   ... presence at  ESC Congress 2015 , where the company is ... EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology with ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... Palatin Technologies,Inc. (AMEX: PTN ) announced today ... trial of PL-3994, a long acting analog of ... decompensated congestive,heart failure (CHF). The trial is being ... to the U.S. Food and Drug,Administration. Future plans ...
... Third Quarter 2007 Earnings release, you are,invited to listen to ... on Tuesday, November 6, 2007 at 9:30 a.m. EST, with ... Chief,Financial Officer. What: QIAGEN N.V. ... Tuesday, November 6, 2007 at 9:30 a.m. EST, ...
Cached Medicine Technology:Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure 3QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web 2
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket ... zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. ... SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
(Date:8/28/2015)... ... 28, 2015 , ... SmartPractice Calendars afford dental ... practice contact information and logos, Calendars stand alone as functional brand-building giveaways ... seasonal mailings, thank you and welcome communications, and to complement statements and invoices. ...
(Date:8/28/2015)... ... August 28, 2015 , ... SharkNinja, ... with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® ... Flavor Extraction™ technology, which delivers a variety of sizes and styles while achieving ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... new computerised screening test for cervical cancer detects more ... a study published on bmj.com today. ,It ... re-tested and might allow for longer intervals in-between testing, ... screening of conventional pap smears for cervical cancer has ...
... perception of older drivers tends to be negative, write ... aged more than 80 consistently show prudent driving behaviours. ... friends, and services and is an independent risk factor ... changes to UK licensing rules should therefore try to ...
... dead'. ,Hackers have disguised the PC worm as ... up-coming book, out on July 21. ,The virus ... drives plugged into computers where users have unwittingly downloaded the ... time the device is inserted. ,Its other effects ...
... has dosed its first patient in a 60-patient Phase ... glutathione peroxidase mimetic, in diabetic patients with a ... for cardiovascular complications. , This dose escalating ... inflammatory cardiovascular biomarkers in patients with an elevated risk ...
... Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, ... Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has ... (FDA) for the treatment of patients with hepatocellular carcinoma ... ,Nexavar is currently approved in more than 50 ...
... Craig Venter Institute (JCVI) today announced the results of ... one type of bacteria into another type dictated by ... online in the journal Science, by JCVI's Carole Lartigue, ... to change one bacterial species, Mycoplasma capricolum into another, ...
Cached Medicine News:Health News:New Cervical Cancer Test Increases the Detection Rate of Abnormal Cells 2Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2Health News:Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: